Biotech entity
Every one of those 1 sits in a single category, pharma. Shanghai Henlius Biotech is most often covered alongside Fosun Pharma, which appears in 1 of these 1 story. They are less corroborated than the beat average, carrying 2 original sources each against 2.5 for the same window.
Last mentioned: Mar 24, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, pharma. Shanghai Henlius Biotech is most often covered alongside Fosun Pharma, which appears in 1 of these 1 story. They are less corroborated than the beat average, carrying 2 original sources each against 2.5 for the same window. At 5, the average consequence score sits below the same-window beat average of 5.9. Shanghai Henlius Biotech appears in 1 tracked Biotech story from March 24, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 20 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Shanghai Henlius Biotech. Shared-story counts are live from our verified record — not editorial picks.
2025 Annual Results
Fosun Pharma officially releases its full-year financial performance for 2025.
US FDA Approval
Key biosimilar assets receive final marketing authorization for the US market.
CAR-T Expansion
Yescarta receives expanded indication approval for second-line treatment in China.
ADC Platform Milestone
First internally developed ADC candidate enters Phase II clinical trials.
Fosun Pharma (2196.HK) reported its 2025 annual results, highlighting a significant shift toward innovative drug revenue and successful international commercialization of its biosimilar portfolio. The company's strategic focus on oncology and high-value therapeutics continues to drive growth despite a challenging global macroeconomic environment.
Source: manilatimes.net · thailand-business-news.com
Shanghai Henlius Biotech is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
